Free Trial
NASDAQ:WHWK

Whitehawk Therapeutics Q3 2025 Earnings Results & Report

Whitehawk Therapeutics logo
$3.02 -0.36 (-10.65%)
Closing price 04:00 PM Eastern
Extended Trading
$3.02 0.00 (0.00%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Whitehawk Therapeutics beat analyst earnings expectations in its Q3 2025 results, released November 6, 2025. The company reported EPS of -$0.26 versus the -$0.51 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
Before Market Opens

Whitehawk Therapeutics EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.51
Beat/Miss
Beat by +$0.25
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 5 quarters

Whitehawk Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Whitehawk Therapeutics Q3 2025 Earnings FAQ

Whitehawk Therapeutics (NASDAQ:WHWK) reported earnings of -$0.26 per share for Q3 2025, beating the consensus estimate of -$0.51. The report was announced on Thursday, November 6, 2025.

Whitehawk Therapeutics Earnings Headlines

Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
See More Whitehawk Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Whitehawk Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Whitehawk Therapeutics and other key companies, straight to your email.

About Whitehawk Therapeutics

Whitehawk Therapeutics (NASDAQ:WHWK) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company’s work centers on precision medicines intended to selectively target diseased cells while limiting damage to healthy tissue.

Whitehawk Therapeutics is advancing a pipeline of investigational therapeutic programs, with development activities focused primarily on oncology. As a clinical-stage company, its product candidates remain subject to preclinical and clinical testing, as well as review by applicable regulatory authorities, before any potential commercialization.

Publicly available information about the company’s specific pipeline, geographic operations, and leadership is limited. Whitehawk Therapeutics is headquartered in the United States and is listed on the Nasdaq under the symbol WHWK.

View Whitehawk Therapeutics Profile